An interventional study of 4D MIOCT integrated into a Zeiss Artevo 800 in Corneal Diseases, Retinal Diseases and Ocular Diseases, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Duke University · Not applicable, Interventional, and Device feasibility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Corneal Diseases with a site in United States — 12 open to participants now, 13 under way, 3 of them phase 3. Corneal Diseases · United States.
Among the 76 studies in Corneal Diseases with a site in United States, this one is the 48th largest by planned enrollment of the 54 interventional ones that give a count, is one of 5 that started in 2025, is one of 23 with no phase, reaches primary completion later than 8 of the 12 other live ones, and was the 73rd registered.
219 studies on the registry are indexed under Corneal Diseases; 43 are open to participants now.
Browse Corneal Diseases studies →12 of the 76 studies in Corneal Diseases with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 20–79 · Healthy volunteers
University of Maryland, Baltimore · Sites in United States
Ages 18+ · Healthy volunteers
Woolfson Eye Institute · Sites in United States
Ages 8+
Optos, PLC · Sites in United States
Ages 22+ · Healthy volunteers
Henry M. Jackson Foundation for the Advancement of Military Medicine · Sites in United States
Ages 21–55
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 33 Corneal Diseases studies recruiting now, 21 (64%) set no upper age limit and 5 (15%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 14 · Phase 4 5
First in 1992; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5 is below the median of 40 across 132 interventional studies indexed under Corneal Diseases.
Median enrollment 79 across the 54 interventional studies, 90 across the 22 observational. Of the 54 that completed or were terminated, 15 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 76 have an industry lead sponsor. The 10 most frequent:
Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.
Duke University has 1 study filed under Corneal Diseases — fewer than ten, so there is no comparison to draw.
6 of the studies in Corneal Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06993597University of Maryland, BaltimoreStudy of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy | 2027-03 |
| NCT03030755The Cleveland ClinicCorneal Elastography and Patient Specific Modeling | 2027-05 |
| NCT06854393Henry M. Jackson Foundation for the Advancement of Military MedicineLacripep for Corneal Wound Healing Study | 2027-06 |
| NCT04439552Boston Children's HospitalfMRI and IVCM Cornea Microscopy of CXL in Keratoconus | 2027-08 |
| NCT07780890Massachusetts General HospitalA Study to Assess Brillouin Hydration Mapping for the Evaluation of Ocular Tissues and Diseases | 2027-09-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 76 studies in Corneal Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study team will conduct the first in-human pilot studies using 4D MIOCT for imaging in the operating room. Building on the earlier integration and wet-lab validations, the researchers will assess the system's ease of use, safety, and visualization of intended structures during various anterior and posterior segment ophthalmic procedures.
The purpose of this project is to capture research images from microscope integrated Optical Coherence Tomography (MIOCT) integrated into a Zeiss Artevo 800 surgical microscope with an add-on investigational 3D OCT scanner (hereafter called the 4D MIOCT) in participants undergoing clinically-indicated surgical procedures for a range of ocular diseases. The researchers will evaluate normal and abnormal microanatomy of the eye, image during surgical procedures, and track subretinal injections for therapeutic delivery during surgery (volumes measured/analyzed from the OCT images after surgery).
This study is an observational imaging study with no treatment interventions for research purposes. The population is 5 adult ophthalmic surgical patients scheduled for eye surgery at Duke Eye Center, Durham. Up to 8 patients may be enrolled due to potential for surgery scheduling changes that would not allow research imaging on a surgery day for up to 3 patients. Research activities consist of investigational 4D MIOCT integrated into Zeiss Artevo 800 imaging of the eyes during surgery and collection of clinical data and other imaging from the participant's medical record, clinical visit and surgical procedure.
Additional imaging of the participant's eye performed for clinical care will be extracted from the medical record for comparison to the intraoperative images. In this initial pilot, comparisons will enable design of future studies for accuracy, precision and reproducibility of the research device in eye surgery.
For study participants there is no additional risk to the participant beyond what is normal for their ophthalmic surgery. No medications or surgical interventions/activities will be performed for research purposes.
Images will be captured during the standard care ophthalmic microsurgery.
This research will utilize the data gathered during OCT imaging performed as described above. The data collected from the OCT systems will be analyzed offline to allow for image processing and alternate visualizations of the area under study. The data gathered from 4D MIOCT imaging will be compared to existing clinical studies (performed as part of standard of care) on the participant, should they exist, for the purpose of identifying whether new information is gained by 4D MIOCT. Researchers will review the participant's Medical Record for up to three eye care visits prior to surgery and record information related to ocular health, eye examinations and imaging and prior ophthalmic treatment. No additional clinical studies will be performed for the purpose of this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Research 4D MIOCT imaging will be performed in the operating room during clinically-indicated surgical procedures. Imaging will be of one or both eyes.
Device: 4D MIOCT integrated into a Zeiss Artevo 800
4D MIOCT integrated into a Zeiss Artevo 800 surgical microscope with an add-on investigational 3D OCT scanner
4D MIOCT ease of use
Determining subjective operator comfort and satisfaction using Likert Scales (Likert scores 1-5)
Time frame: Standard of care visit - day 1
Surgical workflow
Evaluation of surgical workflow/interference using Likert Scales (Likert scores 1-5)
Time frame: Standard of care visit - day 1
Presence of microanatomy as measured by 4D MIOCT image reading
Presence (Yes/No) of retinal anatomy as measured from 4D MIOCT grading
Time frame: Standard of care visit - day 1
Presence of abnormal microanatomy as measured by 4D MIOCT
Combination of presence (Yes/No) and severity (e.g. mild, moderate, severe) of abnormal retinal structures and measured from 4D MIOCT images
Time frame: Standard of care visit - day 1
Plan to share: No — This is a first in-human pilot study using 4D MIOCT in the operating room. There will only be 5 participants enrolled in this study. If further studies are performed after this pilot, we may share IPD.
Started Jul 2025 (actual). Primary completion is estimated for Oct 2027, 27 months after the start.
Of 37 non-industry interventional studies with no phase under Corneal Diseases, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 54. This study's planned 27 months is above that.
Counting every sponsor, half of 43 studies reached it within 22 months; a quarter within 5 and three quarters within 45.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Oct 2026 → Oct 2027 and completion Oct 2026 → Oct 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.